CA3116712A1 - Systemes et procedes de recherche et de traitement du cancer bases sur des donnees - Google Patents
Systemes et procedes de recherche et de traitement du cancer bases sur des donnees Download PDFInfo
- Publication number
- CA3116712A1 CA3116712A1 CA3116712A CA3116712A CA3116712A1 CA 3116712 A1 CA3116712 A1 CA 3116712A1 CA 3116712 A CA3116712 A CA 3116712A CA 3116712 A CA3116712 A CA 3116712A CA 3116712 A1 CA3116712 A1 CA 3116712A1
- Authority
- CA
- Canada
- Prior art keywords
- data
- sequencing
- database
- cancer
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 257
- 238000011282 treatment Methods 0.000 title claims abstract description 250
- 238000011160 research Methods 0.000 title description 42
- 238000012163 sequencing technique Methods 0.000 claims abstract description 137
- 238000007493 shaping process Methods 0.000 claims abstract description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 412
- 201000011510 cancer Diseases 0.000 claims description 216
- 108090000623 proteins and genes Proteins 0.000 claims description 114
- 230000008569 process Effects 0.000 claims description 90
- 230000000694 effects Effects 0.000 claims description 81
- 230000014509 gene expression Effects 0.000 claims description 57
- 210000004027 cell Anatomy 0.000 claims description 56
- 238000002560 therapeutic procedure Methods 0.000 claims description 56
- 210000001519 tissue Anatomy 0.000 claims description 55
- 108020004414 DNA Proteins 0.000 claims description 43
- 230000004927 fusion Effects 0.000 claims description 36
- 230000035772 mutation Effects 0.000 claims description 34
- 238000009169 immunotherapy Methods 0.000 claims description 28
- 238000003559 RNA-seq method Methods 0.000 claims description 27
- 210000004602 germ cell Anatomy 0.000 claims description 27
- 210000002220 organoid Anatomy 0.000 claims description 25
- 230000004044 response Effects 0.000 claims description 22
- 238000001712 DNA sequencing Methods 0.000 claims description 14
- 210000002865 immune cell Anatomy 0.000 claims description 11
- 230000001461 cytolytic effect Effects 0.000 claims description 8
- 230000002018 overexpression Effects 0.000 claims description 8
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 7
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 7
- 239000012661 PARP inhibitor Substances 0.000 claims description 7
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 108020001507 fusion proteins Proteins 0.000 claims description 6
- 102000037865 fusion proteins Human genes 0.000 claims description 6
- 230000037442 genomic alteration Effects 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 238000002659 cell therapy Methods 0.000 claims description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 4
- 238000011369 optimal treatment Methods 0.000 claims description 4
- 101150049668 xt gene Proteins 0.000 claims description 4
- 108700020463 BRCA1 Proteins 0.000 claims description 3
- 102000036365 BRCA1 Human genes 0.000 claims description 3
- 101150072950 BRCA1 gene Proteins 0.000 claims description 3
- 102000052609 BRCA2 Human genes 0.000 claims description 3
- 108700020462 BRCA2 Proteins 0.000 claims description 3
- 101150008921 Brca2 gene Proteins 0.000 claims description 3
- 102100039788 GTPase NRas Human genes 0.000 claims description 3
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 3
- 102000043136 MAP kinase family Human genes 0.000 claims description 3
- 108091054455 MAP kinase family Proteins 0.000 claims description 3
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 3
- 238000009175 antibody therapy Methods 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 3
- 108700042657 p16 Genes Proteins 0.000 claims description 3
- 101150041972 CDKN2A gene Proteins 0.000 claims description 2
- 101150069156 Cdkn2b gene Proteins 0.000 claims description 2
- 101150029707 ERBB2 gene Proteins 0.000 claims description 2
- 101150039808 Egfr gene Proteins 0.000 claims description 2
- 101100435489 Homo sapiens ARID1A gene Proteins 0.000 claims description 2
- 101150105104 Kras gene Proteins 0.000 claims description 2
- 101150073900 PTEN gene Proteins 0.000 claims description 2
- 101150080074 TP53 gene Proteins 0.000 claims description 2
- 210000000601 blood cell Anatomy 0.000 claims description 2
- 108700021358 erbB-1 Genes Proteins 0.000 claims description 2
- 101150046722 idh1 gene Proteins 0.000 claims description 2
- 108700025694 p53 Genes Proteins 0.000 claims description 2
- 238000012800 visualization Methods 0.000 claims description 2
- 108700001666 APC Genes Proteins 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 20
- 239000000047 product Substances 0.000 description 56
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 52
- 238000003556 assay Methods 0.000 description 48
- 238000004458 analytical method Methods 0.000 description 43
- 239000000523 sample Substances 0.000 description 38
- 238000012360 testing method Methods 0.000 description 32
- 230000001225 therapeutic effect Effects 0.000 description 32
- 208000032818 Microsatellite Instability Diseases 0.000 description 31
- 230000004075 alteration Effects 0.000 description 27
- 230000000392 somatic effect Effects 0.000 description 26
- 230000008707 rearrangement Effects 0.000 description 25
- 230000002068 genetic effect Effects 0.000 description 24
- 238000013439 planning Methods 0.000 description 23
- 239000000090 biomarker Substances 0.000 description 22
- 238000003745 diagnosis Methods 0.000 description 21
- 108091092878 Microsatellite Proteins 0.000 description 20
- 239000003814 drug Substances 0.000 description 19
- 108700028369 Alleles Proteins 0.000 description 18
- 238000012015 optical character recognition Methods 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 238000001914 filtration Methods 0.000 description 16
- 238000001514 detection method Methods 0.000 description 14
- 230000000869 mutational effect Effects 0.000 description 13
- 238000004422 calculation algorithm Methods 0.000 description 12
- 238000007481 next generation sequencing Methods 0.000 description 12
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 208000026310 Breast neoplasm Diseases 0.000 description 10
- 238000012512 characterization method Methods 0.000 description 10
- 238000009826 distribution Methods 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- 230000008093 supporting effect Effects 0.000 description 10
- 206010006187 Breast cancer Diseases 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 238000003384 imaging method Methods 0.000 description 9
- 230000010354 integration Effects 0.000 description 9
- 230000009850 completed effect Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 206010061289 metastatic neoplasm Diseases 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 206010060862 Prostate cancer Diseases 0.000 description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 238000004891 communication Methods 0.000 description 7
- 238000010606 normalization Methods 0.000 description 7
- 230000026676 system process Effects 0.000 description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 5
- 238000002483 medication Methods 0.000 description 5
- 230000001394 metastastic effect Effects 0.000 description 5
- 201000002528 pancreatic cancer Diseases 0.000 description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 4
- 102100030708 GTPase KRas Human genes 0.000 description 4
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 4
- 101710104976 Interferon gamma-related Proteins 0.000 description 4
- 102000008070 Interferon-gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 4
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 238000013480 data collection Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 229960003130 interferon gamma Drugs 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 230000033607 mismatch repair Effects 0.000 description 4
- 230000002250 progressing effect Effects 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- 230000009452 underexpressoin Effects 0.000 description 4
- 101150106899 28 gene Proteins 0.000 description 3
- 206010069754 Acquired gene mutation Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 102000001398 Granzyme Human genes 0.000 description 3
- 108060005986 Granzyme Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 3
- 108091034057 RNA (poly(A)) Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000001364 causal effect Effects 0.000 description 3
- 230000008711 chromosomal rearrangement Effects 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 238000013499 data model Methods 0.000 description 3
- 238000013079 data visualisation Methods 0.000 description 3
- 238000013503 de-identification Methods 0.000 description 3
- 230000002357 endometrial effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 208000002409 gliosarcoma Diseases 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000000771 oncological effect Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 229930192851 perforin Natural products 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000007637 random forest analysis Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000037439 somatic mutation Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- -1 ARID IA Proteins 0.000 description 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 2
- 108010009356 Cyclin-Dependent Kinase Inhibitor p15 Proteins 0.000 description 2
- 102000009512 Cyclin-Dependent Kinase Inhibitor p15 Human genes 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 230000004536 DNA copy number loss Effects 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 230000010558 Gene Alterations Effects 0.000 description 2
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 2
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 2
- 101000826399 Homo sapiens Sulfotransferase 1A1 Proteins 0.000 description 2
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 2
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 2
- 102100023986 Sulfotransferase 1A1 Human genes 0.000 description 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000007635 classification algorithm Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000000683 nonmetastatic effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 238000012913 prioritisation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 101150042997 21 gene Proteins 0.000 description 1
- 101150091922 APO gene Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100025618 C-X-C chemokine receptor type 6 Human genes 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 1
- 102100026234 Cytokine receptor common subunit gamma Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010053240 Glycogen storage disease type VI Diseases 0.000 description 1
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 1
- 102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 description 1
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 1
- 208000006050 Hemangiopericytoma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 1
- 206010051922 Hereditary non-polyposis colorectal cancer syndrome Diseases 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000856683 Homo sapiens C-X-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101001055227 Homo sapiens Cytokine receptor common subunit gamma Proteins 0.000 description 1
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 1
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000979599 Homo sapiens Protein NKG7 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000946863 Homo sapiens T-cell surface glycoprotein CD3 delta chain Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 description 1
- 206010069755 K-ras gene mutation Diseases 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 201000005027 Lynch syndrome Diseases 0.000 description 1
- 230000037364 MAPK/ERK pathway Effects 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100029166 NT-3 growth factor receptor Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 101150063858 Pik3ca gene Proteins 0.000 description 1
- 102100023370 Protein NKG7 Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 102100029197 SLAM family member 6 Human genes 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102100035891 T-cell surface glycoprotein CD3 delta chain Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 238000012550 audit Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011220 combination immunotherapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000037437 driver mutation Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000004547 gene signature Effects 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000021991 hereditary neoplastic syndrome Diseases 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 229940126546 immune checkpoint molecule Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 230000009397 lymphovascular invasion Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 244000309459 oncolytic virus Species 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 206010034260 pelvic mass Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000024977 response to activity Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 208000014653 solitary fibrous tumor Diseases 0.000 description 1
- 238000012358 sourcing Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000000547 structure data Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011222 transcriptome analysis Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 108010064892 trkC Receptor Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000012049 whole transcriptome sequencing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Primary Health Care (AREA)
- Data Mining & Analysis (AREA)
- Biomedical Technology (AREA)
- Databases & Information Systems (AREA)
- Pathology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Surgery (AREA)
- Urology & Nephrology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Abstract
Un procédé et un système pour effectuer un séquençage génomique comprend le stockage d'un ensemble de programmes d'application d'utilisateur, chacun des programmes nécessitant un sous-ensemble spécifique d'application de données, pour chacun d'une pluralité de patients, l'obtention de données de système reçues à partir d'une pluralité de sources, les données de système comprenant des données de dossiers cliniques dans des formes d'origine comprenant des informations d'état de maladies, des types de traitement et des informations d'efficacité de traitement, le stockage des données de système dans une première base de données semi-structurée, la mise en forme au moins d'un sous-ensemble des premières données de base de données afin de générer un nouveau produit de données, le stockage du nouveau produit de données dans une deuxième base de données, pour chaque programme d'application d'utilisateur, la sélection du sous-ensemble spécifique d'application de données à partir de la deuxième base de données et le stockage du sous-ensemble spécifique d'application de données dans une structure optimisée pour une interface de programme d'application dans une troisième base de données.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862746997P | 2018-10-17 | 2018-10-17 | |
| US62/746,997 | 2018-10-17 | ||
| PCT/US2019/056713 WO2020081795A1 (fr) | 2018-10-17 | 2019-10-17 | Systèmes et procédés de recherche et de traitement du cancer basés sur des données |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3116712A1 true CA3116712A1 (fr) | 2020-04-23 |
Family
ID=70284254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3116712A Pending CA3116712A1 (fr) | 2018-10-17 | 2019-10-17 | Systemes et procedes de recherche et de traitement du cancer bases sur des donnees |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2019359878A1 (fr) |
| CA (1) | CA3116712A1 (fr) |
| WO (1) | WO2020081795A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023150285A1 (fr) * | 2022-02-04 | 2023-08-10 | Elixirgen Therapeutics, Inc. | Systèmes et méthodes de protocole de thérapie cellulaire |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111816315B (zh) * | 2020-05-28 | 2023-10-13 | 上海市生物医药技术研究院 | 胰腺导管癌状态评估模型构建方法及应用 |
| WO2021247905A1 (fr) * | 2020-06-04 | 2021-12-09 | Xcures, Inc. | Procédés et systèmes pour oncologie de précision utilisant un modèle bayésien à plusieurs niveaux |
| US12119103B2 (en) | 2021-03-30 | 2024-10-15 | Tempus Ai, Inc. | GANs for latent space visualizations |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2245198A1 (fr) * | 2008-02-04 | 2010-11-03 | Massachusetts Institute of Technology | Sélection d'acides nucléiques par hybridation en solution en amorces oligonucléotidiques |
| US20150324527A1 (en) * | 2013-03-15 | 2015-11-12 | Northrop Grumman Systems Corporation | Learning health systems and methods |
| US20140365242A1 (en) * | 2013-06-07 | 2014-12-11 | Siemens Medical Solutions Usa, Inc. | Integration of Multiple Input Data Streams to Create Structured Data |
| US10642854B2 (en) | 2016-10-07 | 2020-05-05 | Sudeep Pattnaik | Clinical data aggregation architecture and platform |
-
2019
- 2019-10-17 AU AU2019359878A patent/AU2019359878A1/en active Pending
- 2019-10-17 CA CA3116712A patent/CA3116712A1/fr active Pending
- 2019-10-17 WO PCT/US2019/056713 patent/WO2020081795A1/fr unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023150285A1 (fr) * | 2022-02-04 | 2023-08-10 | Elixirgen Therapeutics, Inc. | Systèmes et méthodes de protocole de thérapie cellulaire |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019359878A1 (en) | 2021-05-27 |
| WO2020081795A1 (fr) | 2020-04-23 |
| WO2020081795A8 (fr) | 2020-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200258601A1 (en) | Targeted-panel tumor mutational burden calculation systems and methods | |
| US11640859B2 (en) | Data based cancer research and treatment systems and methods | |
| US12112839B2 (en) | Data based cancer research and treatment systems and methods | |
| Beaubier et al. | Integrated genomic profiling expands clinical options for patients with cancer | |
| US20210118559A1 (en) | Artificial intelligence assisted precision medicine enhancements to standardized laboratory diagnostic testing | |
| Nicolosi et al. | Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines | |
| Polubriaginof et al. | Disease heritability inferred from familial relationships reported in medical records | |
| US20230343337A1 (en) | Collaborative artificial intelligence method and system | |
| US20200381087A1 (en) | Systems and methods of clinical trial evaluation | |
| Gymrek et al. | Identifying personal genomes by surname inference | |
| Graff et al. | Cross-cancer evaluation of polygenic risk scores for 16 cancer types in two large cohorts | |
| De Leeuw et al. | Diagnostic interpretation of array data using public databases and internet sources | |
| JP6231654B2 (ja) | 疾患関連ヒトゲノム変異体の解析とレポート作成のシステムと方法 | |
| EP3631657B1 (fr) | Système et procédé de détection de fusion de gènes | |
| Rockowitz et al. | Children’s rare disease cohorts: an integrative research and clinical genomics initiative | |
| CA3116712A1 (fr) | Systemes et procedes de recherche et de traitement du cancer bases sur des donnees | |
| Chandrasekaran et al. | Implementation of multigene germline and parallel somatic genetic testing in epithelial ovarian cancer: SIGNPOST study | |
| Mirshahi et al. | A genome-first approach to characterize DICER1 pathogenic variant prevalence, penetrance, and phenotype | |
| Roy et al. | SeqReporter: automating next-generation sequencing result interpretation and reporting workflow in a clinical laboratory | |
| Yohe et al. | Standards for clinical grade genomic databases | |
| US20230245788A1 (en) | Data based cancer research and treatment systems and methods | |
| Furness | Bridging the gap: the need for genomic and clinical-omics data integration and standardization in overcoming the bottleneck of variant interpretation | |
| Wood et al. | Burden of tumor mutations, neoepitopes, and other variants are dubious predictors of cancer immunotherapy response and overall survival | |
| US20190267114A1 (en) | Device for presenting sequencing data | |
| Alzu'bi | A personal genomic information analysis and management system for healthcare purposes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220920 |
|
| EEER | Examination request |
Effective date: 20220920 |
|
| EEER | Examination request |
Effective date: 20220920 |
|
| EEER | Examination request |
Effective date: 20220920 |
|
| EEER | Examination request |
Effective date: 20220920 |
|
| EEER | Examination request |
Effective date: 20220920 |